Medical/Pharmaceuticals
Mallinckrodt and Terumo Blood and Cell Technologies Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Chronic Graft Versus Host Disease (cGvHD) in Adults
– In a dual-review process, two independent advisory committees to the Australian Minister for Health recommended reimbursement based on a favorable clinical and cost-effectiveness comparison – DUBLIN and LAKEWOOD, Colo., Oct. 28, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global ...
2021-10-28 05:48
2431
Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), in a Two Drug Regimen, Proves Safe and Effective for Critically Ill Hospitalized AIDS Patients
LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...
2021-10-27 20:47
1211
I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its Innovative Assets in China
* I-Mab strategic partnership with Sinopharm will covers all aspects of the go-to-market process, including authorization of more than 300 Sinopharm's subsidiaries as distributors acrossChina. * I-Mab is on track to submit BLA for third line multiple myeloma (MM) treatment by Q4 2021. * The...
2021-10-26 20:00
2933
Qilian International Holding Group Limited Completes Phase One of Its Expansion of New Organic Fertilizer Production Facility and Puts It into Production
JIUQUAN, China, Oct. 26, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), aChina-based pharmaceutical and chemical products manufacturer, today announced that the Company has completed phase one of the expansion of its new organic fertilizer produc...
2021-10-26 20:00
1899
Samsung Biologics Reports Third Quarter 2021 Financial Results
* Q3'21 revenue of KRW 450.7 billion increased 64% compared to Q3'20. * Q3'21 operating profit of KRW 167.4 billion increased 196% compared to Q3'20. * Stable supply, strong operational excellence and a high utilization rate across all plants. * Active investment on expansion, pre-sales ac...
2021-10-26 15:23
2066
Angel Pharmaceuticals Announces Approval of IND Application in China for ITK Inhibitor CPI-818
JIAXING, China and BURLINGAME, Calif., Oct. 25, 2021 /PRNewswire/ -- Angel Pharmaceuticals Co., Ltd. ("Angel Pharma") today announced that its IND application for CPI-818, a small molecule ITK inhibitor, has been approved by the Center for Drug Evaluation (CDE) to initiate clinical trials in pati...
2021-10-26 07:30
1914
SCN9A Antisense Pain Killer OLP-1002 Moves into Phase 2a Stage
SEOUL, South Korea, Oct. 25, 2021 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to initiate a Phase 2a trial for SCN9A antisense pain killer OLP-1002 inAustralia. In the Phase 2a trial of a two stage adaptive design ...
2021-10-25 20:30
1905
111, Inc. Announces Strategic Partnership with Chugai Pharma China Co., Ltd. to Accelerate Innovations in Chronic Disease Management
SHANGHAI, Oct. 25, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced a strategic cooperation agreement with Chugai Phar...
2021-10-25 19:00
2263
Meet the Next Resolution in Medicine -- Polaris Biology Releases Starion™, the next-generation mass cytometer
SHANGHAI, Oct. 23, 2021 /PRNewswire/ -- Polaris Biology, a leading innovator in
single-cell technologies, announced today the largest product launch in company
history with the introduction of the Starion™ Mass Cytometry System.
2021-10-23 15:05
3237
I-Mab Expands U.S. Footprint with New R&D Site in San Diego
- I-Mab will strengthen its global R&D presence, with a new world-class R&D and operational site, located in the heart of the rapidly growingSan Diego biotech hub - The new site will complement I-Mab's Global Clinical Development site in Gaithersburg, Maryland to form an integrated I-Mab US R&...
2021-10-22 20:00
2079
Ping An Good Doctor Unveils Strategic 2.0 Continuum
SHANGHAI, Oct. 22, 2021 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor"; Stock Code: 01833.HK), the leading online medical and healthcare service platform in China, presented its business achievements and unveiled its Strategic 2.0 Continuum at an investor...
2021-10-22 17:08
2759
2021 Bio-enzyme Application Explorer Summit held in Chengdu
The event focuses on innovation and development of biochemical pharmaceuticals CHENGDU, China, Oct. 22, 2021 /PRNewswire/ -- The biochemical pharmaceutical industry is facing unprecedented opportunities and challenges with the changing economic and policy environment inChina and abroad. On Octobe...
2021-10-22 14:23
1592
Akeso is rapidly advancing the clinical study of the PD-1/CTLA-4 bispecific antibody Cadonilimab combined with TIGIT monoclonal antibody for the teratment of solid tumors
HONG KONG, Oct. 21, 2021 /PRNewswire/ -- Akeso, one of leading Chinese pharmaceutical innovation company announces that the first patient was dosed in a phase I clinical trial of the Company's independently developed TIGIT monoclonal antibody (AK127) in combination with the Company's global firs...
2021-10-22 09:50
1658
Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore
SINGAPORE, Oct. 21, 2021 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner withIncyte Biosciences International Sàrl,the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two new medicines for its haematology and onc...
2021-10-22 09:00
1966
Kintor Pharma Announces PD-L1/TGF-β dual-targeting antibody (GT90008) Approved for Advanced Solid Tumour Clinical Trial in China
SUZHOU, China, Oct. 21 , 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the clinical trial of PD-L1/TGF-β dual-targeting antibody (GT90008) fo...
2021-10-21 22:33
2686
Speclipse included in MedTech Outlook rating of top 10 non-invasive device companies
SEOUL, South Korea, Oct. 21, 2021 /PRNewswire/ -- Speclipse, a startup
specializing in laser spectroscopic and AI-based medicaldiagnostic technologies
and a member ofBorn2Global Centre, was recently included in MedTech Outlook's
"Top 10 Non InvasiveDevice Companies" ranking for 2021.
2021-10-21 21:00
7142
Guangzhou Concord Cancer Center Becomes a Designated Hospital of Social Healthcare Insurance
BEIJING, Oct. 21, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone ...
2021-10-21 16:00
9054
Luoxin Pharmaceutical signs licensing agreement with Austria-based Marinomed Biotech AG for Budesolv® Budesonide Nasal Spray
SHANGHAI, Oct. 21, 2021 /PRNewswire/ -- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (''Shandong Luoxin''), a subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd. ("Luoxin Pharmaceutical" or "the company") , signed a licensing agreement withAustria-based Marinomed Biotech AG ("Mar...
2021-10-21 15:58
1692
A Hypercompact CRISPR Technology Developed by GenKOre is deemed a Potential Game Changer in Gene Therapy.
DAEJEON, South Korea, Oct. 20, 2021 /PRNewswire/ -- On September 2, 2021, a
scientific paper from GenKOre on the new hypercompact CRISPR system called
CRISPR/Cas12f-GE was published in an online issue of Nature Biotechnology (IF
54.9), one of the world's top-tier biotechnology journals.
2021-10-21 09:05
1679
GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF-β R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research
PERTH, Australia and TAIPEI and SHANGHAI, Oct. 20, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the first patient with metastatic sigmoid adenocarcinoma has been dosed inPerth, Aus...
2021-10-21 08:05
2098
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 315 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 302 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Most Read
GIGABYTE Strengthens NVIDIA® Partnership to Drive Innovation in AI-Powered Gaming and Creative Solutions
2026-01-17 00:00
7453
